ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
NPS Pharmaceuticals is cutting its staff by 53% as part of a restructuring intended to reduce spending and refocus R&D. The New Jersey-based firm, which has about 490 employees, is also dropping development of its lead product, Preos, a recombinant human parathyroid hormone being developed for osteoporosis. FDA raised questions about the drug earlier this year. NPS says it will focus on teduglutide, a peptide drug that targets gastrointestinal disorders.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X